Earnings Scheduled For August 10, 2022
Companies Reporting Before The Bell
• Wix.com (NASDAQ:WIX) is estimated to report earnings for its second quarter.
Recap of Tuesday’s Biotech Catalysts – End Of The Day Summary
The U.S. Food and Drug Administration (FDA) has granted tentative approval to Avadel Pharmaceuticals’ (NASDAQ: AVDL) lead candidate LUMRYZ (FT218) for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adults with narcolepsy.
Capricor Therapeutics Announces First Patient Dosed In Pivotal Phase 3 Study Of CAP-1002 For Treatment Of Duchenne Muscular Dystrophy
Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select
More Than $27 Million Bet On Seres Therapeutics? 4 Penny Stocks Insiders are Buying
U.S. stock futures traded lower this morning on Friday ahead of jobs report for june. Investors, meanwhile, focused on some notable insider trades.
Earnings Scheduled For May 10, 2022
Companies Reporting Before The Bell
• The Middleby (NASDAQ:MIDD) is expected to report quarterly earnings at $2.10 per share on revenue of $935.99 million.
50 Biggest Movers From Yesterday
Gainers
Hycroft Mining Holding Corporation (NASDAQ: HYMC) shares gained 81.3% to close at $2.32 on Monday. Last week, AMC Entertainment Holdings purchased a major stake in Hycroft Mining Holding.
Mid-Afternoon Market Update: Dow Drops 150 Points; Capricor Therapeutics Shares Plunge
U.S. stocks traded mixed toward the end of trading, with the Dow Jones dropping around 150 points on Monday.
Capricor Stops Work On Exosome-mRNA Based COVID-19 Vaccine Candidate
In its Q4 FY21 earnings press release, Capricor Therapeutics Inc (NASDAQ:
Earnings Outlook For Capricor Therapeutics
Capricor Therapeutics (NASDAQ:CAPR) is set to give its latest quarterly earnings report on Thursday, 2022-03-10. Here's what investors need to know before the announcement.
Analysts estimate that Capricor Therapeutics will report an earnings per share (EPS) of $-0.19.
